Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Roberts & Ryan Inc., America's first Service-Disabled Veteran-Owned (SDVO) broker-dealer, is pleased to welcome Mark DeVito as its Senior Director of Equity Trading.

Roberts & Ryan, Inc.

Mr. DeVito joins Roberts & Ryan as a seasoned business veteran, whose 35-year career has included leadership roles in investment banking, corporate finance, capital market transactions, alternative investments, and corporate boards. Prior to joining Roberts & Ryan, Mr. DeVito was Managing Director of the Global Investment Banking Group at Bank of America Securities, where he developed key client relationships and originated investment banking transactions. Before Bank of America Securities, Mr. DeVito was Managing Partner at JCS Partners LLC. Prior to that, he was Managing Director of Global Energy and Power Investment Banking at Merrill Lynch. Additionally, while at Merrill Lynch, he was the Global Head of their Alternative Investments Group and Managing Director of their Debt Capital Markets Group. Prior to that, he was Senior Vice President of Investment Banking and Capital Markets at Lehman Brothers and Assistant Vice President at Shearson Lehman Hutton. Mr. DeVito served as a member of the Board of Directors of Nextremity Solutions, the Board of Trustees of Rumson Country Day School and the Executive Board of Family and Children’s Services. When asked to share his thoughts on Roberts & Ryan's latest appointment, Chief Executive Officer Ed D'Alessandro remarked, “I am very excited to welcome Mark to our team. His extensive experience and distinguished investment banking career will be a tremendous asset to Roberts & Ryan. Mark is committed to our social mission of supporting Veterans and their families, and his investment banking experience will be instrumental in helping us grow. We are truly fortunate to have someone of Mark’s caliber join our team to help us get to the next level.” Mr. DeVito is a graduate of Fordham University’s Gabelli School of Business, where he received an MBA in Finance, and a graduate of Seton Hall University, where he received a BA in Finance. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, primarily focusing on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

February 08, 2024 09:00 AM Eastern Standard Time

Image

Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech’s Investigational Alzheimer’s Treatment Shows Positive Trial Results

Benzinga

By Meg Flippin, Benzinga Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to slow the effects of life-threatening and chronic aging-related conditions using cellular therapies, is making inroads with Lomecel-B™, its investigational treatment for hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and aging-related frailty. On October 5th, the Miami-based biotech announced that Lomecel-B™ met its primary safety endpoint and showed a lack of deterioration in cognitive or atrophy signals in approximately 50 patients aged 60 to 85 years old with mild Alzheimer’s disease, marking a major milestone for the company. The successful trial paves the way for more clinical studies of this potentially game-changing treatment. “We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” Wa’el Hashad, CEO of Longeveron, said announcing the trial results. In late December, the company released additional new clinical and biomarker results from the trial that reinforced the earlier top-line findings. Additional analysis of cognitive function and daily living data showed favorable results with Lomecel-B™ over placebo. The drug was shown to slow and in some cases improve certain measurements of cognitive function (MoCA, MMSE). Funding Development In addition to reporting promising results for Lomecel-B™, in October 2023, Longeveron secured $4 million in gross proceeds before expenses from a round of equity financing. In late December, Longeveron closed a previously announced registered direct offering of 1.35 million shares priced at $1.62 per share, raising an additional $2.36 million in gross proceeds. Longeveron plans to use the net proceeds to fund the ongoing clinical and regulatory development of Lomecel-B™ and for capital expenditures, working capital, and general corporate purposes. The company reported that as of the end of the third quarter, it has enough existing cash and short-term investments to cover expenses and capital requirements into the first quarter of 2024. Investor Aspirations And Stock Trend Some investors are hopeful that Lomecel-B™ could possibly play a role in the future in treating Alzheimer’s disease, which affects about 6.7 million people 65 and older in the U.S. In 2023 alone, Alzheimer’s and other dementias will cost the U.S. $345 billion, according to the Alzheimer’s Association. By 2050, total payments for healthcare, long-term care and hospice for those with dementia are projected to reach nearly $1 trillion. Lomecel-B™ appears to target inflammation, and it is believed that inflammation plays a role in the onset and progression of Alzheimer’s disease. Researchers made this discovery after several studies showed that people who took anti-inflammatory drugs like Enbrel and Humira were as much as 50% less likely to develop Alzheimer's disease later in life. These discoveries have in part helped to spur a new class of investigational drugs that aim to treat and cure Alzheimer’s disease by targeting inflammation. Lomecel-B™ is made from medical signaling cells (MSCs) derived from the bone marrow of healthy adult donors. It is believed that these cells travel to sites of damage or inflammation in the body and promote cellular regeneration and repair. More Potential Catalysts On The Horizon? Lomecel-B™ as a potential treatment for Alzheimer’s isn’t the only possible catalyst on the horizon for Longeveron, and investors may want to watch for more to come. The therapeutic treatment is also in stage 2 trials to treat Hypoplastic Left Heart Syndrome (HLHS) and Aging-related frailty. HLHS is a rare pediatric congenital heart defect that affects about 1,000 babies in the U.S. annually. The left side of the heart fails to develop in patients with HLHS – leading to short-term mortality, delayed development and long-term organ failure. Lomecel-B™ is administered directly into the cardiac tissue of the right ventricle for HLHS patients. The goal is to improve cardiac function through the regenerative, pro-vascular and anti-inflammatory effects of MSCs. Results from a phase 1 ELPIS 1 trial showed 100% survival in Lomecel-B™-treated children at up to five years of age. Historically, children with HLHS have about 20% mortality by five years. The results were encouraging enough for Lomecel-B™ to be given the Rare Pediatric Disease Designation (RPD), Orphan Drug Designation (ODD) and Fast Track Designation from the FDA. A phase 2 trial in HLHS of 38 patients is currently underway. In August, the trial surpassed the 50% enrollment threshold. The company is also in a phase 2 trial of Lomecel-B™ to treat aging-related frailty, which is characterized by mobility disability, weakness, fatigue, weight loss, slowness and low activity. Its current phase 2 trial will include 45 patients in Japan, where nearly a third of the population is over 65. “With our Phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our Phase 2 program in Aging-related frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B™,” said Hashad. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 08, 2024 08:45 AM Eastern Standard Time

Cannara Biotech Q1 Results: Revenue, Net Income And Market Share Up, Quarter Also Marks Company’s First Export Sale

Benzinga

By Meg Flippin, Benzinga With the demand for high-quality, affordably priced cannabis growing in Canada, Cannara Biotech Inc.'s (OTCMKTS: LOVFF) investments seem to be paying off. The vertically integrated producer of premium-grade cannabis and derivative product offerings has used investment dollars to produce quality cannabis products and increase the number of growing zones. That has resulted in Montreal-based Cannara Biotech reporting record-setting revenue for its first quarter and forecast even more growth to come in 2024. For the first quarter ending November 30, 2023, Cannara posted net revenue of $19.5 million, an 89% year-over-year increase and net income of $2.1 million, up significantly from $2,954 in the year-ago first quarter. Meanwhile, gross profit before fair value adjustments of $7.9 million was up 98% from the year-ago first quarter and earnings before interest, taxes, depreciation and amortization (EBITDA) of $5.2 million marked a 206% increase. “Our first quarter results are continued solid proof of Cannara's strong financial health and strategic approach to business operations,” Nicholas Sosiak, CFO of Cannara said when reporting quarterly results. ”We have seen impressive sales increases and a steady rise in adjusted EBITDA, net income and cash flow from operations, which sets a strong base for the rest of the year.” Quality Cannabis At An Affordable Price Since launching in 2017, Cannara Biotech has been focused on growing quality cannabis products and bringing them to the masses at an affordable price. The company operates two huge facilities spanning over 1,650,000 square feet in Quebec, where it churns out quality cannabis products en masse using its access to low-priced utilities in the province and lean operational structure to keep costs down. It then passes on those savings to its legions of customers. During the first quarter, the company produced from nine growing zones out of its Valleyfield Facility with a 10th growing zone added in January. All told, the company has increased its total production to about 33,500 kg of cannabis per year. That should be welcome news to its investors given sales of cannabis products in Canada are projected to grow at a CAGR of 13.4% between 2021 and 2030. Underscoring that demand, Cannara said it sold 1.34 million units across its three flagship brands during the first quarter, up 99% from the 675,000 units sold in the same period a year ago. Quarter-over-quarter units sold were up 11%. The variety of its product line is also increasing, which could drive sales further in 2024. During the quarter it increased its total national product portfolio of cannabis products by 60% to 155 SKUs from 97. It is innovating in new categories including infused pre-rolls, milled flower and budget-friendly vapes. Market Share Gains Along with an increase in sales during the quarter were market share gains, a key metric given it’s difficult to stand out in the market thanks to climates that make it hard to grow the product, regulatory hurdles and high start-up costs. In Quebec, Canada’s largest market for cannabis, Cannara is the fourth-largest licensed producer, controlling about 8.7% of the market as of the first quarter. In Ontario, it ranks as the ninth top producer and in Alberta, its market share has increased to 2.3% from 1.2% share in the year-earlier first quarter. In British Columbia, it's making inroads, with market share of just under 1%. The company is still at the beginning of its growth, with only 35% of its production capacity activated, and operates in only five main markets in Canada, resulting in many strategies in Cannara’s toolkit to potentially increase its revenues and market share quarter over quarter. Another milestone for Cannara during the first quarter: it completed its first intentional export sale of cannabis product to Israel. Not only does that showcase its ability to be an exporter, it highlights an additional potential revenue stream for the company. A Bright Future Ahead? Looking out to the remainder of 2024, the company plans to increase production capabilities and sales incentives, roll out new products including new formats, release new strains, increase market penetration and continue to post positive Adjusted EBITDA. It’s confident all of that should position it for solid results this year and beyond. "The first quarter of 2024 has been another significant period for Cannara, with record breaking net revenues of $19.5 million, an 89% increase from the comparative quarter in 2023, and an incredible net income surge,” Zohar Krivorot, President and Chief Executive Officer, said of the first quarter results. “As we build on this momentum in 2024, our roadmap is clear, continued execution with excellence, cost efficiencies and product innovation. This strategic expansion is not just about quantity, it is about deepening our market penetration by enriching our customers’ experience with high-quality products that stand out in the market. With a keen eye on evolving market trends and consumer preferences, we are committed to growing our market presence and product portfolio in a purposeful manner." Featured photo courtesy of Cannara Biotech. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 08, 2024 08:30 AM Eastern Standard Time

Image

Redx Pharma lands biggest deal to date with sale of KRAS inhibitor programme to Jazz Pharma

Redx Pharma PLC

Redx Pharma PLC CEO Lisa Anson joins Proactive's Stephen Gunnion with details of a landmark partnership with Jazz Pharmaceuticals, marking its largest deal to date. Anson explained the agreement involves the sale of Redx's KRAS programme, a key preclinical discovery initiative targeting genetic mutations driving various cancers. The $10 million upfront deal could potentially be followed by a further $870 million in milestone payments, signifying a major step forward for Redx in cancer research. The KRAS programme focuses on combating hard-to-treat cancers, such as colorectal, lung, and pancreatic cancers, by targeting specific genetic mutations. The partnership aligns with RedX's strategy to balance in-house program development with collaborations that accelerate patient access to new treatments. Anson emphasised the significance of partnerships in advancing their clinical-stage biotech research and development efforts. The deal not only provides immediate financing but also ensures Redx maintains a vested interest in the program's success through potential milestones and mid-single digit royalties on future sales. Looking ahead, RedX anticipates a busy 2024 with several key milestones, including advancing its fibrosis and oncology programs, further demonstrating its commitment to addressing unmet medical needs. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 08, 2024 06:47 AM Eastern Standard Time

Video

Futura Medical marks pivotal year with first meaningful revenue from Eroxon sales

Futura Medical PLC

Futura Medical PLC CEO James Barder tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company as it rolled out its innovative sexual health product, Eroxon, designed to treat erectile dysfunction. The over-the-counter availability of Eroxon distinguishes it as a groundbreaking product globally, facilitating easier access for consumers without a prescription. Barder noted the company reported significant achievements in 2023, including revenue of £3.1 million and a strategic expansion into the US market, bolstered by FDA approval and a partnership with leading OTC distributor Halen. This expansion is underscored by successful launches in the UK and Belgium, capturing around a 20% market share. Barder highlighted Futura's virtual organizational model and risk-mitigated marketing strategy through partnerships focusing on advertising and promotional spend. Looking ahead, Futura anticipates further global expansion with more than ten country launches expected by April, surpassing initial forecasts. Additionally, the company's vigilant stance against counterfeit products underscores its commitment to safeguarding brand integrity and consumer trust. With new broker and investor relations appointments, Futura aims to enhance shareholder value and visibility. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 08, 2024 06:31 AM Eastern Standard Time

Video

Poolbeg Pharma's new VP of Clinical Operations Laura Maher aims to help progress development assets

Poolbeg Pharma PLC

Poolbeg Pharma PLC's newly appointed Vice President of Clinical Operations Laura Maher joined Proactive's Stephen Gunnion to discuss her role at the company. Maher detailed her responsibilities at Poolbeg, emphasising her leadership in developing and managing clinical programs. She highlighted the importance of collaborations, both internally and with external service providers, to ensure the acquisition of quality data. Maher's significant achievements at Amryt include her pivotal role in the development and approval of Filsuvez, a treatment for Epidermolysis Bullosa (EB). She oversaw the largest-ever EB trial, leading to EMA approval in June 2022, marking it as the world’s first approved treatment for EB. Despite initial FDA rejection, her perseverance led to eventual FDA approval in December 2023. Her extensive background in clinical research and operations, beginning with a research master's degree and experience in various roles across academia and small pharmaceutical companies, informs her approach at Poolbeg. Maher expressed her enthusiasm for working in a dynamic environment like Poolbeg, particularly excited about their cancer immunotherapy and cytokine release syndrome projects. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 08, 2024 06:27 AM Eastern Standard Time

Video

News Release

Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its platform technology to develop treatments for different neurodegenerative diseases and a potential cure for diabetes, has been granted a patent from the Indian Patent and Trademark Office for its cell therapy technology. The cell sorting patent will be protected until November 2036 for the company's innovative cell selection and enrichment technology. This patent covers the production of IsletRx, the company's product for the treatment and potential cure for diabetes. The company's technology is unique with its ability to select and enrich only the highest functioning and purest islet cells from the population of differentiated islet-like cells which enables the maximum therapeutic effect. According to the Indian Ministry of Home Affairs, CNN and the pharmaletter India is a fastest growing economy of the global G20 with massive investments in web infrastructure and growing pharma and biotech sectors. As such biotech companies are increasingly securing their IP in India to ensure maximal potential revenues in the Indian subcontinent[1]. The approval of this patent in India is particularly important, especially in light of our collaboration project with iTolerance, a US company in the diabetes field and funded by the BIRD Foundation. The project combines Kadimastem’s and iTolerance’ s technologies to develop and commercialize a breakthrough regenerative technology to cure diabetes without the need for life-threatening chronic immuno-suppression. The project received a US $1Million grant from the BIRD Foundation for this project. Out of a total budget of US $2 Million In addition, according to statista in 2021, India was ranked second in the world with about 74.2 million diabetic adults in the 20 to 79 years old age group. The number of diabetic individuals was projected to increase to over 124 million in 2045[2]. In financial year 2021, the market size of diabetes and pre-diabetes care market in India was valued at about 17 billion U.S. dollars. It is forecasted to reach about 34 billion dollars in 2026 and 59 billion dollars in 2031[3]. Asaf Shiloni, company CEO: “Kadimastem highly believes that the company’s treatment can improve the quality of lives for hundreds of thousands of those dealing with the daily struggles of insulin dependent diabetes (IDD) by presenting a potential cure for IDD with our unique patented solution with IsletRx cells.” In May 2021, the selection technology covered by this patent was described in a peer-reviewed journal article [4] in Frontiers in Endocrinology. About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About IsletRx The IsletRx product is a clinical-grade collection of pancreatic islet cells. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas and enables the insulin dependent patient to avoid an abnormal drop in sugar level (hypoglycemia). In addition, the method of production and selection of the cells enables their implantation in various types of smaller size devices, suitable for maximum comfort for people living with diabetes. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Social Media: LinkedIn, Twitter, Facebook [1] Press Information Bureau (pib.gov.in); Indian economy regains its swagger as China stumbles | CNN Business; India's booming bioeconomy poised for growth (thepharmaletter.com) [2] https://www.statista.com/statistics/1360381/india-number-of-adults-with-diabetes/ [3] https://www.statista.com/statistics/1359258/india-diabetes-and-pre-diabetes-care-market-size/ [4] https://www.frontiersin.org / articles/10.3389/fendo.2021.635405/full Contact Details Kadimastem Asaf Shiloni CEO s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

February 07, 2024 07:23 AM Eastern Standard Time

Primer Selected for the 2024 GSV Cup 50

Spark Metro PR

Primer has been named to the 2024 GSV Cup 50 out of 1,000 nominations of pre-seed and seed-stage companies. The GSV Cup, presented by Google Cloud and GSV Ventures, and supported by HolonIQ, recognizes the world's most innovative digital learning and workforce skills startups. The GSV Cup 50 will be featured at the 15th Annual ASU+GSV Summit, the preeminent global gathering for “Pre-K to Gray” education leaders, in San Diego, CA. The GSV Cup 50 highlights the most promising startups that support learners across the Pre-K to Gray spectrum, distributed across early childhood education, K-12, higher education, workforce learning, and adult consumer learning. All nominees were evaluated against GSV’s “Five P’s” framework: People, Product, Potential, Predictability, and Purpose. "Being chosen for the GSV Cup 50 is a great honor, highlighting our alignment with GSV's values and our commitment to innovation in digital learning,” said Mark Naufel, Founder of Primer. “Being part of this elite group starts a new chapter for Primer, as we continue to revolutionize the idea of a lifelong adaptive learning experience powered by an AI personal companion." “This year’s GSV Cup was both incredibly competitive and incredibly inspiring,” said Deborah Quazzo, Managing Partner of GSV Ventures and Co-founder of the ASU+GSV Summit. “The GSV Cup 50 are undoubtedly the stars of tomorrow. With almost 80% of the companies focused on leveraging AI, they’ve got both eyes on the future of education – not just what we can see now, but what we can build beyond view. We’re so excited to see the transformative effects of these companies over the next five, ten, even fifteen years.” The 2024 GSV Cup 50 companies are poised to make a global impact, with 34% headquartered outside of the United States and representation from 15 unique countries. This year’s GSV Cup 50 also represent a variety of diverse perspectives and experiences, with 66% of the companies led by female or BIPOC founder(s). The GSV Cup 50 join a prestigious group of past Cup startups, including Ello, Ethena, LingoAce, Prenda, Stride, TransfrVR, and TeachFX. See Primer and all of the companies selected to the GSV Cup 50 at https://www.asugsvsummit.com/gsv-cup. About Primer Primer is an AI personal companion poised to revolutionize the digital learning landscape, with the market expected to reach heights of $370 billion by 2026. Leveraging a patent-pending, generative AI system, Primer offers tailored, engaging experiences that enhance both learning and daily life. Beyond traditional education, Primer learns and grows with each user, continuously evolving to meet their personal needs. It’s this seamless ability to customize learning for everyone, from inquisitive schoolchildren to professionals advancing their careers, that underscores Primer’s dedication to ensuring no one navigates through life without a worldclass advocate. About ASU+GSV Summit Now celebrating its 15th year, the ASU+GSV Summit has become the world's most important and impactful gathering of leaders across "Pre-K to Gray" education and workforce learning. Hosted in San Diego, the annual event attracts over 7,000 in-person and 10,000 virtual registrants. Past GSV keynote speakers and honorees have included Presidents George Bush, Barack Obama and Vicente Fox Quesada, Former Secretaries of Education Arne Duncan and John King, Surgeon General Vivek Murthy, Gina Raimondo, Reed Hastings, John Legend, Condoleezza Rice, Justice Sandra Day O'Connor, Priscilla Chan, Laurene Powell Jobs, and more. ### For Media Relations contact: Mark Naufel,, info@primer.net Contact Details Primer Mark Naufel +1 302-597-6768 info@primer.net Company Website https://primer.net/

February 07, 2024 12:10 AM Eastern Standard Time

Image

Prodigy Biotech Enters into a Partnership Agreement with Leading Cancer Center to Advance Products to Improve Outcomes in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Prodigy Biotech

Prodigy is the first company to join the MSK Therapeutic Accelerator. The accelerator program launch was announced at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024. Prodigy and Memorial Sloan Kettering Cancer Center (MSK) will co-develop a product targeting Enterococcus sp. to treat microbial dysbiosis in patients undergoing allogenic hematopoietic stem cell transplantation. The product will be built on Prodigy’s polyclonal Immunoglobulin Y (IgY) technology that has shown promising preclinical data in models of alcoholic liver disease. Prodigy and MSK have entered into a sponsored research agreement through the MSK Therapeutics Accelerator program to evaluate Prodigy’s product candidate for the improvement of outcomes in patients undergoing allogenic hematopoietic stem cell transplantation (allo-HCT). The MSK Therapeutic Accelerator project will be led by Jonathan Peled, MD, PhD, Assistant Attending Physician, MSK. Through his pioneering research, Dr. Peled and his team at MSK have significantly advanced the role of the microbiome in impacting outcomes in patients undergoing allo-HCT. Dr. Peled’s work revealed that patients undergoing allo-HCT have enterococcal domination events and these domination events lead to worse overall survival and higher graft vs. host disease (GvHD)-related mortality. Dr. Peled has previously demonstrated in preclinical models that resetting the gut microbiome has profound outcomes in mitigating disease severity. In this collaboration, Prodigy’s Enterococcus sp. neutralizing antibodies will be evaluated in preclinical models of GvHD and product candidates will be developed to move into clinical development. Furthermore, Prodigy is pleased to have Dr. Peled join and help build its allo-HCT Scientific Advisory Board (SAB). In addition to the sponsored research, MSK will provide expertise and institutional resources through the MSK Therapeutics Accelerator to aid in the development of a drug candidate for patients undergoing allogenic hematopoietic stem cell transplantation. MSK’s Therapeutic Accelerator Program is a partnership program between MSK and technology and pharmaceutical companies to advance novel therapeutics through all stages of drug development. The program brings together innovative healthcare companies with MSK’s community of clinical and scientific experts to establish groundbreaking collaborations that can have a tangible impact on treatment or management of cancer. Satish Chandran, CEO of Prodigy said, “ We are delighted to collaborate and partner with MSK’s Therapeutic Accelerator Program and Dr. Peled to develop product(s) for patients undergoing allo-HCT. Given the significant morbidity and mortality associated with the disease, it is incumbent upon all of us to find solutions that have the potential to save lives and restore normalcy to these patients. We have been very pleased with the robust preclinical proof-of-concept data of our product PROD-AH-001, (Hepatology, 2023) for alcoholic hepatitis which is currently being readied for an IND submission with the FDA.” Dr. Jonathan Peled of MSK said, "Patients who are treated with allo-HCT experience the most extreme microbiome injuries observed in any clinical setting. There is an urgent need to develop approaches that can mitigate this and prevent the expansion of potentially pathogenic bacteria. We hypothesize that attenuating the expansion of Enterococcus within the gastrointestinal tract will prevent bloodstream infections with this bacterium and potentially also ameliorate GVHD.” Dr. Chandran presented information about this important new collaboration at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024. About Allogenic Hematopoietic Stem Cell Transplantation Allo-HCTs have a chance to cure malignancies but are associated with high rate of complications and mortality. Allo-HCT can lead to various complications, affecting different organs due to the intense conditioning regimen and introduction of foreign immune cells. A significant concern after allo-HCT is graft-versus-host disease (GvHD), where the donor's immune cells mount an attack against the recipient and is a major cause of morbidity and non-relapse mortality in this patient population. There is a clear need of therapies that are able to improve outcomes in patients undergoing allogenic hematopoietic stem cell transplantation. About Prodigy Biotech, Inc. Prodigy Biotech is a privately held biopharmaceutical company focused on developing products using its polyclonal Immunoglobulin Y technology to selectively edit the microbiome while avoiding deleterious effects to the commensal microflora. The versatility of avian antibodies, IgY, allows for pathogen- specific neutralization capabilities not only to bacteria but also viruses, fungi, endotoxins, and even human secreted proteins such as cytokines and chemokines. A target agnostic approach and strategic collaborations with leading researchers in the microbiome field has allowed Prodigy to build a diverse pipeline ranging from modulating the gut microbiome in alcoholic liver disease (ALD) to modulating the lung microbiome in chronic obstructive pulmonary disease (COPD). Cautionary Note on Forward-Looking Statements: This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Contact Details Prodigy Biotech, Inc. Satish Chandran satish.chandran@prodigybiotech.com Company Website https://www.prodigybiotech.com/

February 06, 2024 10:00 AM Eastern Standard Time

1 ... 47 48 49 50 51 ... 251